liver cancer
MHRA awards Innovation Passports to liver cancer and dementia medicines
August 7, 2026Innovation Passports, MHRA, liver cancer
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that two investigational medicines targeting liver cancer and dementia with …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
July 30, 2025Medical Communications, Research and Development AstraZeneca, NHS, National Institute for Health and Care Excellence, Oncology, dual immunotherapy, hepatocellular carcinoma, liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for its dual immunotherapy …
AstraZeneca’s Imfinzi meets primary endpoint for liver cancer treatment
November 13, 2023Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, liver cancer
AstraZeneca has announced positive results from the EMERALD-1 phase 3 trial for Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) …
Transgene terminates oncolytic IO combo trial in advanced liver cancer
August 8, 2019Research and Development Cancer, Transgene, clinical trials, liver cancer, pharma
Biotech firm Transgene has announced its decision to terminate a study investigating the efficacy of its oncolytic immunotherapy product Pexa-Vec …
Eisai and MSD’s Lenvima recommended for NHS Scotland in advanced or unresectable liver cancer
April 8, 2019Manufacturing and Production, Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, liver cancer, pharma
Patients in Scotland with with advanced or unresectable hepatocellular carcinoma (HCC) will now be able to access Eisai and MSD’s …
Keytruda falls short at Phase 3 in advanced liver cancer
February 20, 2019Research and Development Cancer, MSD, keytruda, liver cancer, pharma
MSD has revealed new Phase 3 data which indicates that its blockbuster immunotherapy Keytruda (pembrolizumab), in combination with best supportive …
NICE recommends Lenvima as alternative first-line therapy for advanced liver cancer
December 19, 2018Research and Development, Sales and Marketing Lenvima, NICE, UK, liver cancer, pharma
UK drug watchdog NICE has revealed that it has recommended Eisai’s Lenvima (lenvatinib) for use on the NHS in England …
Eisai’s Lenvima wins over NICE in liver cancer in just three months
November 9, 2018Medical Communications, Sales and Marketing Cancer, Eisai, Lenvima, Levantinib, NHS, NICE, UK, liver cancer, pharma
Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now …
Ipsen reveals positive Phase 3 data of Cabometyx in liver cancer
July 5, 2018Research and Development Cabometyx, Cancer, ipsen, liver cancer, pharma
French pharmaceutical company Ipsen has announced that The New England Journal of Medicine has published the results of a Phase …
Research unveils new drug targets for more effective treatment of liver disease
August 22, 2017Manufacturing and Production, Research and Development life sciences, liver, liver cancer, liver disease, pharma, pharmaceuticals
Researchers from KTH The Royal Institute of Technology and Gothenburg University have identified new drug targets in the treatment of …
Bayer’s liver cancer drug availability spreads to UK with NICE approval
August 10, 2017Sales and Marketing Bayer, Cancer, NICE, Nexavar, life sciences, liver cancer, pharma, pharmaceutical
NICE has announced that it has given final appraisal recommending Bayer’s Nexavar (sorafenib) for the treatment of advanced hepatocellular carcinoma …
FDA approves first new drug for liver cancer in decade
April 28, 2017Medical Communications, Sales and Marketing Bayer, Stivarga, hepatocellular carcinoma, liver cancer
The FDA has announced that it has approved the first new treatment for hepatocellular carcinoma (HCC), a type of liver …
Bayer says its Stivarga improved overall survival in liver cancer in late-stage trials
June 30, 2016Research and Development, Sales and Marketing Bayer, Stivarga, drug trial, liver cancer
German pharma and crop sciences giant Bayer (ETR: BAYN) said late-stage trials for its drug to treat liver cancer showed a …
Bayer’s liver cancer drug meets primary endpoint in late stage trial
May 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Stivarga, late stage trial, liver cancer, phase III, regorafenib, trial
Bayer has announced positive results from a late-stage trial evaluating Stivarga (regorafenib) tablets for the treatment of patients with unresectable …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
